Andrew Schiermeier, Ph.D. to Resign as Executive Vice President and Chief Operating Officer of Intellia Therapeutics, Inc
June 22, 2021 at 07:16 am EDT
On June 21, 2021, Andrew Schiermeier, Ph.D., Executive Vice President and Chief Operating Officer of Intellia Therapeutics, Inc. informed the Company that he will be resigning from his position in order to accept the position of President and Chief Executive Officer of a new autologous and allogeneic universal chimeric antigen receptor (CAR") T-cell therapy company.